Related Experiment Video

Updated: Feb 17, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

666

Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF

Tetsuro Tsujimoto1, Hiroshi Kajio1

  • 1Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.

Journal of the American College of Cardiology
|December 2, 2017
PubMed

Insights

Abdominal obesity increases the risk of death in patients with heart failure with preserved ejection fraction (HFpEF). This study found a significantly higher mortality risk for HFpEF patients with abdominal obesity.

Area of Science:

  • Cardiology
  • Obesity Research
  • Clinical Outcomes

Background:

  • Limited research exists on the link between abdominal obesity and outcomes in heart failure with preserved ejection fraction (HFpEF).
  • Abdominal obesity is a prevalent condition with potential implications for cardiovascular health.

Purpose of the Study:

  • To investigate the association between abdominal obesity and the risk of all-cause mortality in patients diagnosed with HFpEF.
  • To quantify the increased mortality risk associated with abdominal obesity in this specific patient population.

Main Methods:

  • Utilized data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.
  • Defined abdominal obesity by waist circumference (men ≥102 cm, women ≥88 cm).
  • Employed multivariable Cox proportional hazard models to analyze all-cause mortality, adjusting for relevant covariates.

Main Results:

  • Included 3,310 HFpEF patients; 2,413 had abdominal obesity.
  • Patients with abdominal obesity had a significantly higher risk of all-cause mortality (adjusted HR: 1.52; 95% CI: 1.16 to 1.99; p=0.002).
  • Increased risks were also observed for cardiovascular and noncardiovascular mortality in those with abdominal obesity.

Conclusions:

  • Abdominal obesity is a significant risk factor for increased all-cause mortality in patients with HFpEF.
  • These findings underscore the importance of addressing abdominal obesity in the management of HFpEF patients.
  • Further research may explore targeted interventions for abdominal obesity in HFpEF.
Abstract

Keywords:
TOPCAT trialabdominal obesityall-cause mortalityheart failure with preserved ejection fractioninflammation

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
374
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
301
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
278
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197